A Phase 4 interventional study of Angiotensin Receptor Blockers and Placebo in Aortic Stenosis and Aortic Valve Stenosis, sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval. Recruiting at 2 sites in 2 countries. Open to participants aged 20 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-12-20.
Sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Aortic Valve Stenosis with a site in Canada — 23 open to participants now, 36 under way, 1 of them phase 3. Aortic Valve Stenosis · Canada.
Among the 87 studies in Aortic Valve Stenosis with a site in Canada, this one is the 43rd largest by planned enrollment of the 60 interventional ones that give a count, is one of 3 that started in 2020, is one of 2 in phase 4, reaches primary completion later than 19 of the 35 other live ones, and was the 66th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →23 of the 87 studies in Aortic Valve Stenosis with a site in Canada are open now. Recruiting first, the newest first:
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Sites in Canada
Ages 18+
Kardigan, Inc. · Sites in Canada, United States
Ages 50+
World Health Research Inc. · Sites in Canada, Australia, Colombia and 5 more countries
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Sites in Canada
Ages 18–80
Novartis Pharmaceuticals · Sites in Canada, United States, Austria and 12 more countries
Ages 50–80
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 20 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 7 · Phase 4 2
First in 2002; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 144 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 300 across the 60 interventional studies, 320 across the 27 observational. Of the 44 that completed or were terminated, 18 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 87 have an industry lead sponsor. The 10 most frequent:
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval is the lead sponsor of 15 studies on the registry; 9 are open to participants now.
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval has 5 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Aortic Valve Stenosis with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06991517World Health Research Inc.A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm | 2026-12 |
| NCT06816888Ottawa Heart Institute Research CorporationImpact of Automatic Prompts in Echocardiographic Reports on Referral to Cardiology | 2026-12-01 |
| NCT04464655McGill University Health Centre/Research Institute of the McGill University Health CentreA 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease | 2026-12-19 |
| NCT04913870Institut universitaire de cardiologie et de pneumologie de Québec, University LavalAngiotensin Receptor Blockers in Aortic Stenosis | 2027-02 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 8 to your calendar (.ics) → With an account.
Among the 87 studies in Aortic Valve Stenosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is intended to investigate the effect of angiotensin receptor blockers (ARBs) on mild-to-moderate aortic stenosis.
Studies support the concept that activation of the renin-angiotensin system may be involved in the progression of valve stenosis and myocardial fibrosis in aortic stenosis. Furthermore recent studies have shown that renin-angiotensin system medication may slow down aortic stenosis progression rate and left ventricle remodeling.
Thus the present study is a randomized control trial to test the efficacy of the angiotensin receptor blocker (ARB) to slow down aortic stenosis progression and left ventricular remodeling/dysfunction in patients with mild-to-moderate aortic stenosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Angiotensin Receptor Blockers will be given orally once a day for 2 years.
Drug: Angiotensin Receptor Blockers
Participants will receive a matched placebo orally once a day for 2 years.
Other: Placebo
Angiotensin Receptor Blockers treatment for 2 years.
Placebo administration for 2 years.
Change in the anatomic progression of aortic stenosis
Aortic valve calcification (measured by MDCT)
Time frame: Baseline, 2 years
Change in peak aortic jet velocity
peak aortic jet velocity (Echocardiography)
Time frame: Baseline, 2 years
Change in aortic valve area
Aortic valve area (Echocardiography)
Time frame: Baseline, 2 years
Change in left ventricular (LV) dimension
LV dimension (Echocardiography, MRI)
Time frame: Baseline, 2 years
Change in left ventricular (LV) mass
LV mass (Echocardiography, MRI)
Time frame: Baseline, 2 years
Change in left ventricular (LV) fibrosis
LV Fibrosis (MRI)
Time frame: Baseline, 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2020 (actual). Primary completion is estimated for Feb 2027, 84 months after the start.
Of 25 phase 4 interventional studies under Aortic Valve Stenosis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's planned 84 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Angiotensin receptor blockers (ARBs)
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval